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ABSTRACT
Introduction: To characterise the detailed phenotypic
and comorbid characteristics of participants with
rheumatoid arthritis (RA) in the large population-based
UK Biobank, thereby enabling future longitudinal
analyses.
Methods: We undertook a cross-sectional study using
baseline data from the unique UK Biobank resource
(n=502 649). RA was based on self-report, and type of
medication was used as a proxy measure of valid
diagnosis. Participants with and without RA were
compared in terms of sociodemographic, lifestyle and
other disease-related risk factors. Logistic regression
models were used to determine whether participants
with RA were more likely to report comorbid
conditions, and whether this varied by RA severity. The
models were adjusted for potential confounders and
lifestyle risk factors.
Results: At baseline, 5657 (1.13%) eligible UK
Biobank participants reported RA of whom 2849
(0.57%) had medically treated RA (median
duration=10 years). Prevalence was significantly higher
among female, South Asian and socioeconomically
deprived participants. Participants with RA were
significantly more likely to report diabetes (covariate-
adjusted OR 1.18, 95% CI 1.06 to 1.32, p<0.01),
hypertension (OR 1.19, 95% CI 1.21 to 1.27, p<0.001)
and cardiovascular disease (OR 1.52, 95% CI 1.39 to
1.67, p<0.001).
Conclusions: UK Biobank provides extensive data
concerning RA population-level comorbidity and risk
factors. The frequency, distribution and characteristics
of participants reporting RA in UK Biobank are largely
consistent with other studies. It provides a unique
opportunity to interrogate biomarkers, genetic data,
detailed imaging and linkage to clinical records at the
population level across primary and secondary care.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic
inﬂammatory syndrome that causes pain,
swelling and, if untreated, progressive
damage to joints. The UK prevalence of RA
has been estimated as 0.8%1 which equates
to ∼690 000 people. In addition to disability
and poorer quality of life, RA is also asso-
ciated with increased morbidity and mortality
compared with the general population.2 The
leading cause of death among RA patients is
cardiovascular disease, with risk 50% higher
than the general population.3
UK Biobank is a very large general popula-
tion cohort study of middle-to-older-aged
adults in the UK designed to be
Key messages
What is already known about this subject?
▸ Rheumatoid arthritis (RA) is associated with sig-
nificant cardiometabolic and psychiatric
comorbidities that require long-term studies to
evaluate.
▸ UK Biobank is a large population-based cohort
study that offers opportunities to study chronic
diseases.
What does this study add?
▸ This is the first report of the baseline character-
istics of the RA population in UK Biobank.
▸ The prevalence of RA in UK Biobank is 1.13%
by self-report and 0.57% by medication.
▸ Patients with RA were significantly more likely to
report diabetes, hypertension and cardiovascular
disease.
How might this impact on clinical practice?
▸ UK Biobank emphasises the burden of RA and
comorbidities, highlighting the need for ongoing
vigilance and management.
▸ UK Biobank will be an invaluable resource for
the longitudinal study of RA and related
comorbidities, especially as genetic and other
results become available.
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representative of the general population in terms of age,
sex, socioeconomic status and ethnicity. It was created to
provide a useful resource to study a wide range of
important chronic conditions of adulthood, such as RA.
Follow-up is being conducted via linkage to routine
administrative data sources such as primary care atten-
dances, hospital admissions, drug prescriptions and
death certiﬁcates and will, in due course, provide infor-
mation on incident cases of RA. Genetic, biomarker and
imaging data will also become available in future which
will greatly enhance the studies that can be undertaken
using the UK Biobank cohort. However, because of the
age criteria used, large numbers of participants already
have prevalent diseases such as RA at recruitment, per-
mitting cross-sectional studies to be undertaken now. It
is vital to determine the baseline characteristics of the
participants with a speciﬁc condition such as RA before
subsequent studies can be undertaken and their rele-
vance and signiﬁcance deduced. The aim of this study
was to ascertain the frequency and distribution of
reported RA within this very large general population
cohort study, and the extent to which it was associated
with comorbid conditions. Our work provides a compre-
hensive baseline evaluation on which many subsequent
analyses on this uniquely phenotyped and genotyped
cohort (for around n=150 000 and the rest due in Q3
2016) can be performed.
METHODS
Data collection and definitions
UK Biobank recruited 502 649 participants, aged 37–
73 years, between 2006 and 2010. Baseline assessments
were conducted at 22 study centres located across the
UK.4 UK Biobank has generic ethics approval from the
North West Multicentre Ethics Research Committee
(approval letter dated 17 June 2011, Ref 11/NW/0382).
Participants completed touchscreen questionnaires to
provide information on sociodemographic factors
(including age, sex, ethnicity and postcode of resi-
dence), lifestyle (including smoking status and alcohol
intake) and medical history (including musculoskeletal,
cardiovascular and psychiatric conditions). Postcode of
residence is used to derive Townsend scores,5 a measure
of area-based socioeconomic deprivation. Census data
on the percentage of households without a car,
overcrowded, not owner occupied and containing
unemployed residents are converted into z scores which
are summated to provide a Townsend score. The
Townsend scores are then used to derive socioeconomic
quintiles for the general population. Therefore, the post-
code of residence of participants could be used to cat-
egorise them into general population socioeconomic
deprivation quintiles. Ethnicity was self-reported. Indian,
Pakistani and Bangladeshi participants were categorised
as South Asian. Physical activity was self-reported and
weighted for intensity:6 self-reported minutes of walking
(×3.3), moderate exercise (×4.0) and vigorous exercise
(×8.0). These were then summated to create an overall
physical activity score. Study centre staff collected infor-
mation on current medication and obtained a number
of measurements, including height, weight and blood
pressure. Participants removed their shoes and heavy
outer clothing before weight and height were measured.
Weight was measured, to the nearest 0.1 kg, using the
Tanita BC-418 MA body composition analyser. Height
was measured using a Seca 202 height measure. Body
mass index (BMI) was derived from weight (kg)/(height
(m)×height (m)). The maximum heart rate during exer-
cise variable is described in detail on the UK Biobank
website (http://biobank.ctsu.ox.ac.uk/crystal/ﬁeld.cgi?
id=6033). Brieﬂy, participant ECG readings were taken
during cycling and recovery, where the ‘maximum’
score relates to the highest reading taken throughout.
Participants self-reported their alcohol intake as
‘never’; ‘special occasions only’; ‘one to three times a
month’; ‘once or twice a week’; ‘three or four times a
week’; ‘daily or almost daily’. Smoking status was self-
reported as ‘never’; ‘past’; ‘current’. Alcohol intake
and smoking status were treated as ordinal variables
after removing participants who preferred not to
answer.
RA was deﬁned as self-report of the condition; UK
Biobank did not collect information on disease severity.
Therefore, type and ‘intensity’ of medication was used
as a proxy measure of valid diagnosis and ‘severity’,
stratiﬁed into no RA medication; corticosteroids only;
one synthetic disease-modifying antirheumatic drug
(DMARD) such as methotrexate or sulfasalazine; more
than one synthetic DMARD; and one or more biologic
DMARD such as anti-tumour necrosis factor (TNF)
therapy or rituximab. The full list of eligible drugs
recorded by UK Biobank is contained in the online
supplementary table S1. We checked the UK Biobank
medication list for drugs recorded under trade names;
this was rare, but instances are indicated in the table.
Participants on combination treatments were grouped
according to the highest intensity of medication type
based on the aforementioned list. Medications were
self-reported.
Diabetes, hypertension, cardiovascular disease and
depression were based on self-report. Participants self-
reported use of lipid/cholesterol-lowering and antihy-
pertensive medication. Participants who did not report
hypertension but had measured diastolic blood pres-
sure above 90 or systolic blood pressure above
140 were also categorised as having hypertension.
Cardiovascular disease included angina, myocardial
infarction, arrhythmias, pericarditis, cardiac failure,
valve disease and cardiomyopathy. Participants reported
whether they had suffered pain for more than
3 months at a number of sites: no pain, headache,
facial, neck or shoulder, back, stomach, hip, knee or
pain all over. These data were used to categorise parti-
cipants into no pain, 1 site, 2–3 sites, 4–7 sites or all
over the body.
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Statistical analyses
Participants with and without RA were compared, in
terms of their characteristics, lifestyle factors and pres-
ence of comorbidity, using χ2 tests for categorical data,
χ2 tests for trend for ordinal data and Kruskal–Wallis
tests for continuous data. We used a series of binary
logistic regression analyses to examine the association
between RA and comorbid conditions adjusted for the
potential confounding effects of age, sex, ethnicity and
socioeconomic deprivation quintile, as well as potential
shared lifestyle risk factors of smoking status, alcohol
intake and BMI.
Among those with RA, we used χ2 tests for trend to
examine whether the characteristics of participants and
the prevalence of comorbidity varied according to the
type of RA medication, a surrogate marker of RA severity.
Participants were excluded from these analyses if their
medication was unknown. We undertook generalised
ordered logistic regression analyses (GOLOGIT2; http://
www3.nd.edu/~rwilliam/gologit2/) to explore the rela-
tionship between severity of RA and pain, after adjust-
ment for potential confounders and shared lifestyle risk
factors. GOLOGIT2 has the advantage of not assuming a
stable relationship between an ordered group variable
and outcome.7 We used the ‘autoﬁt’ option to relax the
parallel-lines constraint where appropriate.
As RA was deﬁned on the basis of self-report, it is pos-
sible that some participants with joint symptoms may not
have had RA or may have had another musculoskeletal
condition that they erroneously labelled as RA.
Therefore, we ran the analyses using two deﬁnitions of
RA. First, we assume that all participants who reported RA
had the condition. Second, we used a much tighter deﬁn-
ition which included only those participants who
reported having RA and were also on relevant medication
which rheumatologists would commonly use in RA (see
online supplementary table S1). Participants who
reported RA but were not recorded as taking relevant
medication were excluded from the second analyses. In
both sets of analyses, we compared participants with those
who did not report RA. We also reran all the analyses
excluding the participants who reported osteoarthritis
and then also excluding the participants who reported
other musculoskeletal conditions, including psoriatic
arthritis, systemic lupus erythematosus, ankylosing spon-
dylitis and polymyalgia rheumatic. Finally, we reran the
analyses classifying as hypertensive only those participants
who reported having the condition. These rerun analyses
were not meaningfully different from the ﬁnal results
which are shown. All analyses were conducted using
STATAV.13.1 (StataCorp, College Station, Texas, USA).
RESULTS
Overall
Of the 502 649 UK Biobank participants, 5657 (1.13%)
reported having RA. Of these, 2808 (49.64%) were on
no medication; 22 (0.39%) were on steroids only, 1699
(30.03%) were on one synthetic DMARD only, 1009
(17.84%) were on >1 synthetic DMARD; and 119
(2.10%) were on biologics. Therefore, the prevalence of
treated RA was 0.57%. The median duration of reported
RA was 10 years (IQR 4–20).
Reported RA prevalence was higher in women than
men, overall (1.44% vs 0.74%) and by age strata (see
online supplementary table S2). Compared with white
participants (1.13%), the prevalence was higher among
South Asian participants (1.35%), and lower in black
(0.90%) and Chinese (0.50%). There was a gradient
across the socioeconomic quintiles, from 1.42% in the
most deprived participants to 0.99% in the least
deprived. Participants with reported RA were more likely
to smoke but drank alcohol less frequently (table 1).
Those with reported RA had lower physical activity and
higher maximum heart rates during exercise (table 2).
Participants with RA reported increased use of blood
pressure-lowering and cholesterol/lipid-lowering medica-
tion (table 1).
For men and women, we found signiﬁcant associations
between reporting RA and adiposity-related measures—
higher BMI, waist circumference, percentage body fat
and waist:hip ratio. As additional analysis, we ran linear
regressions between RA status and each, adjusted for the
covariates of age, sex and smoking and the associations
remained. When we used the narrower deﬁnition of
treated RA and compared this subgroup with participants
who did not report RA, all of the associations remained
statistically signiﬁcant, except there was no difference
between groups in terms of physical activity score and
BMI in men (table 2). Women that reported RA were sig-
niﬁcantly more likely to report hormone replacement
therapy, menopause at all, menopause before the age of
50 and having had a hysterectomy (table 2).
Participants with reported RA had lower grip strength
(table 2). They were signiﬁcantly more likely to report
pain, and those with pain were more likely to report it at
more than one site or all over the body (table 3).
Among participants who reported RA, the number of
pain sites increased with increasing RA severity as
deﬁned by medication type (table 4). These ﬁndings
persisted after adjustment for age, sex, ethnicity, socio-
economic quintile, BMI and alcohol intake (table 4).
Participants with reported RA had higher systolic blood
pressure (table 2). The prevalence of hypertension was
higher among those with reported RA (68.04% vs
60.30%; table 3). There was no clear pattern in relation
to RA severity based on type of medication (table 5).
Overall, participants with reported RA had a higher
prevalence of diabetes (7.87% vs 5.25%), and this sur-
vived correction for variables we considered as con-
founding (table 3). The prevalence of cardiovascular
disease was signiﬁcantly higher among those with RA,
and rates increased with higher severity based on medi-
cation except for biologics (table 6). There was a signiﬁ-
cantly increased rate of depression in participants that
reported RA, although this did not persist after
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adjustment for potential confounders and did not reach
statistical signiﬁcance using the tighter deﬁnition of
treated RA (table 6).
The results were very similar when we reran the ana-
lyses excluding RA participants who reported other mus-
culoskeletal conditions such as psoriatic arthritis (n=33),
systemic lupus erythematosus (n=41), polymyalgia (n=35)
and osteoarthritis (n=607), and also when we classiﬁed
hypertension purely on the basis of self-report.
Participants additionally self-reported use of nonsteroidal
anti-inﬂammatory drugs (NSAIDs) and cyclooxygenase-2
(COX-2) inhibitors. We report usage rates in the online
supplementary table S3, stratiﬁed by RA group. There
were signiﬁcantly increased rates of usage in the narrow
and broad RA groups (both p<0.001).
DISCUSSION
Within UK Biobank, the overall prevalence of RA was
1.13% based on self-report and 0.55% using a narrower
deﬁnition of treated RA. These are similar to population
prevalence estimates based on strict American College
of Rheumatology criteria. In a systematic review pub-
lished in 2006, 19 studies had measured prevalence
using these criteria.8 Gabriel et al9 reported a prevalence
of 1.1% for the USA, and all the other studies produced
a prevalence below 1%. Only two studies have been con-
ducted in the British Isles, and none in the past
12 years. In 1999, Power et al10 derived a prevalence of
0.5% for Dublin, Ireland, and, in 2002, Symmons et al1
published a ﬁgure of 0.9% for Norfolk, England.
Whereas these studies used clinician diagnosis of RA,
UK Biobank relies on self-reported diagnosis of RA and
use of relevant medication. It should be noted that we
could not distinguish between participants that chose
not to report (or did not remember) their diseases or
medications and those that were genuinely healthy and
had nothing to report. We assumed that participants
who did not report RA or relevant medication did not
in fact have RA; however, this may not necessarily be the
Table 1 Characteristics of participants with and without rheumatoid arthritis
No rheumatoid arthritis
n=496 992 (98.87%)
All self-reported
rheumatoid arthritis
n=5657 (1.13%)
Treated rheumatoid
arthritis
n=2849 (0.57%)
n (%) n (%) p Value n (%) p Value
Sex
Female 269 516 (54.23) 3951 (69.84) 269 516 (54.23)
Male 227 476 (45.77) 1706 (30.16) <0.001 227 476 (45.77) <0.001
Deprivation quintile
1 (least deprived) 99 710 (20.09) 998 (17.67) 538 (18.90)
2 99 171 (19.98) 981 (17.37) 507 (17.81)
3 99 275 (20.00) 1086 (19.23) 589 (20.70)
4 99 303 (20.01) 1155 (20.45) 581 (20.41)
5 (most deprived) 98 916 (19.93) 1427 (25.27) <0.001 631 (22.17) 0.002
Missing 617 10 3
Ethnicity
White 467 503 (96.02) 5327 (96.14) 2716 (97.00)
South Asian 9755 (2.00) 133 (2.40) 58 (2.07)
Black 8009 (1.65) 73 (1.32) 22 (0.79)
Chinese 1593 (0.33) 8 (0.14) 0.004 4 (0.14) 0.001
Missing 10 132 116 49
Lipid/hypertensive medication use
Yes 61 156 (87.66) 4228 (75.19) 2103 (73.82)
No 434 389 (12.34) 1395 (24.81) <0.001 731 (25.66) <0.001
Missing 1447 34 15
Smoking status
Current 52 278 (10.58) 711 (12.68) 326 (11.53)
Ex 242 911 (49.17) 2850 (50.84) 1493 (52.81)
Never 198 854 (40.25) 2045 (36.48) <0.001 1008 (35.66) <0.001
Missing 2949 51 22
Alcohol
Daily/almost daily 100 983 (20.38) 811 (14.37) 385 (13.53)
3–4 times/week 114 531 (23.11) 928 (16.44) 412 (14.48)
1–2 times/week 127 937 (25.82) 1387 (24.57) 750 (26.36)
1–3 times/month 55 182 (11.14) 689 (12.21) 363 (12.76)
Occasional 57 074 (11.52) 958 (16.97) 476 (16.73)
Never 39 794 (8.03) 872 (15.45) <0.001 459 (16.13) <0.001
Missing 1491 12 4
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Table 2 Characteristics of male and female participants with and without rheumatoid arthritis
No rheumatoid
arthritis
n=496 992 (98.87)
All self-reported
rheumatoid
arthritis
n=5657 (1.13)
p Value
Treated
rheumatoid
arthritis
n=2849 (0.57%)
p ValueMedian (IQR) Median (IQR) Median (IQR)
Men
Age (years) 58 (50–64) 61 (55–65) <0.001 62 (56–66) <0.001
Systolic blood pressure (mm Hg) 141 (130–154) 144 (131–157) <0.001 144 (131–156) 0.005
Diastolic blood pressure (mm Hg) 84 (77–91) 84 (77–91) 0.176 83 (76–90) 0.167
Maximum heart rate during exercise 110 (98–121) 109 (89–121) 0.608 111 (91–125) >0.999
Physical activity score 2625 (1434–5040) 2946 (1493–5946) 0.014 2610 (1464–5500) 0.541
Body mass index 27.30 (24.98–30.06) 27.97 (25.47–30.85) <0.001 27.49 (35.07–30.31) 0.353
Waist circumference (cm) 96 (89–103) 99 (91–107) <0.001 98 (90–106) <0.001
Waist:hip ratio 0.93 (0.89–0.98) 0.95 (0.91–0.99) <0.001 0.95 (0.91–0.99) <0.001
Percentage body fat 25.4 (21.6–29.1) 27 (23.5–31) <0.001 26.9 (23.2–30.8) <0.001
Grip strength score 38 (32–44) 32 (22–44) <0.001 28 (19–36) <0.001
Women
Age (years) 57 (50–63) 60 (55–65) <0.001 61 (55–65) <0.001
Systolic blood pressure (mm Hg) 135 (122–150) 139 (126–153) <0.001 140 (127–155) <0.001
Diastolic blood pressure (mm Hg) 80 (73–88) 81 (74–88) <0.001 80 (74–88) 0.068
Maximum heart rate during exercise 115 (102–126) 100.5 (88–125) <0.001 109 (84.5–122) <0.001
Physical activity score 2514 (1448.5–4533) 2628 (1504–4866) 0.123 244 (1377–4106) 0.120
Body mass index 26.11 (23.45–29.72) 27.22 (24.02–31.29) <0.001 26.78 (23.75–30.74) <0.001
Waist circumference (cm) 83 (75–92) 86 (78–96) <0.001 85 (77–95) <0.001
Waist:hip ratio 0.81 (0.77–0.86) 0.83 (0.78–0.88) <0.001 0.83 (0.78–0.88) <0.001
Percentage body fat 36.8 (32–41.4) 39 (34–43.5) <0.001 38.7 (33.8–43.4) <0.001
Grip strength score 22 (18–26) 16 (10–21) <0.001 12 (8–19) <0.001
Parity N (%) N (%) N (%)
Nulliparous 50 458 (18.78) 674 (17.13) 366 (17.79)
Multiparous 218 243 (81.22) 3261 (82.87) 0.008 1691 (82.21) 0.254
Missing 815 16 4
Hormone replacement therapy
No 165 994 (61.94) 1946 (49.68) 1002 (48.90)
Yes 101 980 (38.06) 1971 (50.32) <0.001 1047 (51.10) <0.001
Missing 1542 34 12
Had menopause
No 63 651 (23.70) 444 (11.29) 225 (10.94)
Yes 162 661 (60.58) 2780 (70.67) 1487 (72.32)
Hysterectomy 30 610 (11.40) 575 (14.62) 283 (13.76)
Not known 11 599 (4.32) 135 (3.43) <0.001 61 (2.97) <0.001
Missing 995 17 5
Age at menopause (years)
<50 56 580 (37.21) 1093 (42.09) 567 (40.94)
50 23 781 (15.64) 386 (14.86) 210 (15.16)
>50 71 706 (47.15) 1118 (43.05) <0.001 608 (43.90) 0.015
Missing 117 449 1354 676
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Table 3 Frequency of comorbid conditions among participants with and without rheumatoid arthritis
No rheumatoid
arthritis
n=496 992
All self-reported
rheumatoid arthritis
n=5657
p Value
Treated rheumatoid
arthritis
n=2849
p Valuen (%) n (%) n (%)
Pain
None 196 103 (39.63) 1049 (18.66) 547 (19.32)
1 site 136 293 (27.54) 1052 (18.71) 504 (17.80)
2–3 sites 125 644 (25.39) 1816 (32.30) 887 (31.33)
4–7 sites 28 644 (5.80) 967 (17.20) 407 (14.38)
All over body 8107 (1.64) 739 (13.14) <0.001 486 (17.17) <0.001
Missing 2159 34 18
Diabetes
No 468 450 (94.75) 5173 (92.13) 2635 (92.98)
Yes 25 966 (5.25) 442 (7.87) <0.001 199 (7.02) <0.001
Missing 2576 42 15
Hypertension
No 197 330 (39.70) 1808 (31.96) 906 (31.80)
Yes 299 662 (60.30) 3849 (68.04) <0.001 1943 (68.20) <0.001
Missing 0 0
Cardiovascular disease
No 467 343 (94.03) 5078 (89.76) 2528 (90.63)
Yes 29 649 (5.97) 579 (10.24) <0.001 267 (9.37) <0.001
Missing 0 0
Depression
No 469 172 (94.40) 5263 (93.04) 2680 (94.07)
Yes 27 820 (5.60) 394 (6.96) <0.001 169 (5.93) 0.439
Missing 0 0
χ2 for trend for pain; χ2 for other variables.
Table 4 Generalised ordered logistic regression analysis of the association between rheumatoid arthritis and pain score site
Pain vs no pain >1 vs ≤1 site ≥4 vs <4 sites Whole body vs ≤7 sites
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Univariate
No RA 1.00 1.00 1.00 1.00
All self-reported RA 2.86*** (2.68 to 3.06) 3.43*** (3.25 to 3.62) 5.42*** (5.12 to 5.75) 9.08*** (8.38 to 9.84)
No RA 1.00 1.00 1.00 1.00
Treated RA 2.74*** (2.50 to 3.01) 3.47*** (3.21 to 3.74) 5.36*** (5.30 to 6.21) 12.44*** (11.26 to 13.75)
No RA 1.00 1.00 1.00 1.00
Steroids only 6.70*** (3.04 to 14.78) 6.70*** (3.04 to 14.78) 6.70*** (3.04 to 14.78) 6.70*** (3.04 to 14.78)
1 synthetic DMARD 2.52*** (2.24 to 2.83) 3.16*** (2.87 to 3.49) 5.35*** (4.82 to 5.93) 11.34*** (9.93 to 12.94)
>1 synthetic DMARD 3.15*** (2.67 to 3.71) 3.92*** (3.44 to 4.47) 6.13*** (5.37 to 7.00) 14.03*** (11.96 to 16.45)
Biologic DMARD 2.89*** (1.82 to 4.60) 4.20*** (2.86 to 6.16) 8.42*** (5.83 to 12.14) 15.16*** (9.69 to 23.74)
Multivariate
No RA 1.00 1.00 1.00 1.00
All self-reported RA 2.58*** (2.41 to 2.76) 3.04*** (2.87 to 3.22) 4.43*** (4.17 to 4.71) 6.99*** (6.43 to 7.61)
No RA 1.00 1.00 1.00 1.00
Treated RA 2.52*** (2.30 to 2.78) 3.12*** (2.288 to 3.38) 4.86*** (4.46 to 5.28) 10.17*** (9.15 to 11.29)
No RA 1.00 1.00 1.00 1.00
Steroids only 5.32*** (2.36 to 11.96) 5.32*** (2.36 to 11.96) 5.32*** (2.36 to 11.96) 5.32*** (2.36 to 11.96)
1 synthetic DMARD 2.34*** (2.08 to 2.64) 2.86*** (2.59 to 3.17) 4.61*** (4.14 to 5.15) 9.42*** (8.21 to 10.81)
>1 synthetic DMARD 2.84*** (2.41 to 3.36) 3.49*** (3.05 to 3.99) 5.03*** (4.38 to 5.78) 11.19*** (9.45 to 13.25)
Biologic DMARD 2.72*** (1.71 to 4.34) 3.97*** (2.68 to 5.88) 7.34*** (5.02 to 10.72) 12.90*** (8.16 to 20.37)
Multivariate: adjusted for age, sex, ethnicity, deprivation quintile, smoking, body mass index and alcohol intake.
**p<0.01; ***p<0.001.
DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis.
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case, resulting in a slight underestimation of RA in the
sample. In this way, we believe our analysis comparing
treated RA with the rest of the population is conservative
and therefore robust.
In UK Biobank, the female to male ratio of the preva-
lence of self-reported RA was 2.3:1. In Alamanos et al’s8
systematic review, all of the studies demonstrated a
higher prevalence in women with the female to male
ratio ranging from 1.6:1 to 5.7:1. The only British study
to report sex-speciﬁc prevalence rates demonstrated a
female to male prevalence ratio of 2.5:1, which is very
close to our ﬁndings in UK Biobank.1 Ethnic differences
were also observed in UK Biobank. Compared with
white participants, the prevalence was higher in South
Asian participants and lower in black and Chinese. This
is consistent with other studies that have reported a low
prevalence among Chinese,11 Taiwanese,12 South
Korean,13 black14 and black Caribbean communities,15
ranging from 0.1 to 0.3 per 100 population in different
Asian groups (eg, Far Eastern).16
UK Biobank participants who reported RA were more
likely to have cardiovascular disease, with an adjusted
OR of 1.52 (vs non-RA participants). This ﬁnding is
consistent with previous studies. Ogdie et al17 conducted
a general population cohort study using routine
primary care data. They studied a composite outcome
of myocardial infarction, stroke or cardiovascular death
among 41 752 participants with RA. In comparison with
participants without RA, those with RA were at
increased risk irrespective of whether they were taking
a DMARD (adjusted HR 1.58, 95% CI 1.46 to 1.70) or
not (adjusted HR 1.39, 95% CI 1.28 to 1.50). Similarly,
QRISK2 data, which included 531 family practitioners,
2.29 million participants and 140 115 cardiovascular
events,18 demonstrated that RA was a signiﬁcant risk
factor for stroke among men (OR 1.34, 95% CI 1.19 to
1.51) and women (OR 1.33, 95% CI 1.22 to 1.46). RA
was also a risk factor for cardiovascular disease among
men (OR 1.38, 95% CI 1.25 to 1.52) and women (OR
1.50, 95% CI 1.39 to 1.61). Hence, UK Biobank data
on cardiovascular disease prevalence seem to be in
broad agreement with other major datasets, lending
external validity. RA was associated with signiﬁcantly
increased rates of NSAID/COX-2 inhibitor use.
Interpretation of NSAID use is problematic because
these are often taken on a pro re nata basis and NSAIDs
such as ibuprofen are available as over-the-counter
drugs.
It has been suggested that RA and cardiovascular
disease may share a genetic predisposition mediated via
common inﬂammatory and metabolic pathways.19 20
However, common lifestyle risk factors may also play a
role. In a systematic review, Sugiyama et al21 demonstrated
a signiﬁcant association between current smoking and RA
in men (OR 1.87, 95% CI 1.49 to 2.34) and women (1.31,
95% CI 1.12 to 1.54). In our study, participants with RA
Table 5 Frequency of comorbid conditions by severity of rheumatoid arthritis
Steroids only 1 synthetic DMARD >1 synthetic DMARD Biologic DMARD
n=22 n=1699 n=1009 n=119
n (%) n (%) n (%) n (%) p Value
Pain
None 3 (13.64) 349 (20.69) 173 (17.25) 22 (18.49)
1 site 2 (9.09) 314 (18.61) 171 (17.05) 17 (14.29)
2–3 sites 10 (45.45) 517 (30.65) 328 (32.70) 32 (26.89)
4–7 sites 3 (13.64) 239 (14.17) 141 (14.06) 24 (20.17)
All over body 4 (18.18) 268 (15.89) 190 (18.94) 24 (20.17) 0.150
Missing 0 12 6 0
Diabetes
No 21 (95.45) 1574 (92.97) 929 (92.90) 111 (93.28)
Yes 1 (4.55) 119 (7.03) 71 (7.10) 8 (6.72) 0.972
Missing 0 6 9 0
Hypertension
No 5 (22.73) 533 (31.37) 329 (32.61) 49 (32.77)
Yes 17 (77.27) 1166 (68.63) 680 (67.39) 80 (67.23) 0.721
Missing 0 0 0 0
Cardiovascular disease
No 19 (86.36) 1564 (92.05) 866 (87.81) 113 (94.96)
Yes 3 (13.64) 135 (7.95) 123 (12.19) 6 (5.04) 0.001
Missing 0 0 0 0
Depression
No 21 (95.45) 1608 (94.64) 940 (93.16) 111 (93.28)
Yes 1 (4.55) 91 (5.36) 69 (6.84) 8 (6.72) 0.439
Missing
χ2 for pain; χ2 for trend for other variables.
DMARD, disease-modifying antirheumatic drug.
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had a higher prevalence of smoking, and adjustment for
potential shared lifestyle risk factors, such as smoking
status, somewhat attenuated the association between RA
and cardiovascular disease in terms of effect size, suggest-
ing these may explain some of the association.
People with RA have a higher prevalence of some
established risk factors for cardiovascular disease, but
not others.22 Boyer et al conducted a meta-analysis of 15
case–control studies, comprising a total of 2956 people
with RA; notably in UK Biobank alone, we have nearly
the same number of participants in one single cohort
and of course multiple number of non-RA participants.
Boyer reported a higher prevalence of smoking and dia-
betes, but not hypertension. We observed a signiﬁcantly
higher prevalence of diabetes in participants that
reported RA. UK Biobank will report glycosylated hemo-
globin (HbA1c) results on all participants in 2016, and
these data will allow better assessment of the association
of RA and its severity with glycaemic levels, and whether
there is an increased risk of undiagnosed diabetes or
impaired glucose tolerance. In contrast to Boyer et al,
the prevalence of hypertension was signiﬁcantly higher
among UK Biobank participants with RA, and the sub-
group on RA medication remained at signiﬁcantly
higher risk of hypertension after adjusting for potential
measured confounders. This is similar to what has been
reported by other studies.23
Overall, there was no association between self-reported
RA and depression. This ﬁnding is not consistent with
previous studies and merits further study. In 2013,
Matcham et al24 published a meta-analysis of 72 studies
comprising 13 189 participants. The pooled prevalence
of depression was 16.8% (95% CI 10% to 24%), but the
estimates of prevalence varied considerably according to
case deﬁnition up to a maximum of 38.8% based on
studies using the Patient Health Questionnaire-9
(PHQ-925). Coexistence of depression and RA is asso-
ciated with increased pain, fatigue, reduced health-
related quality of life, increased physical disability and
healthcare costs.26 However, depression tends to be
underdiagnosed by clinicians. In a cohort study of more
than 33 000 patients with RA, depressive symptoms were
reported by 11.7% of patients but only identiﬁed by 1%
of rheumatologists.27 Similarly, the incidence of depres-
sive symptoms was 7.8 per 100 patient-years based on
patient report, but only 0.4 per 100 patient-years based
on rheumatologist reports. The UK Biobank results are
based on self-reported depression, and it is possible that
people who participate in cohort studies like UK
Biobank are unrepresentative of the general population
and less likely to feel or report depression.
Of the participants who reported RA, 51% were not
on relevant RA medication. Cohorts recruited from sec-
ondary care settings28 report much higher prevalence
(>90%) of DMARD use, but data from inception cohorts
of patients presenting with inﬂammatory arthritis in the
community29 report lower rates of DMARD usage
(<60%), consistent with our ﬁndings.
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It is not currently possible to formally conﬁrm the
diagnosis of RA or stratify RA by disease activity scores,
inﬂammatory markers or self-reported severity in UK
Biobank. Therefore, we used type and intensity of RA
therapy as a proxy measure of disease severity, on the
assumption that more potent RA therapies, such as com-
bination DMARDs or biologic agents, would be used by
participants with the most severe disease. This approach
could be partially confounded by the more widespread
use of treat-to-target strategies resulting in patients with
more recently diagnosed RA receiving combination
DMARDs earlier than patients with more long-standing
disease. Patients who self-reported RA but were on no
RA medication are the group in whom conﬁrmation of
the diagnosis, via biomarkers, imaging and clinical
examination, is most warranted, whereas those on medi-
cations are highly likely to have genuine RA. The former
group is likely to include people who do not have a true
diagnosis of RA (eg, mislabelling of osteoarthritis), but
may also include some people with long-standing RA
who are unable to take or no longer require DMARD
therapy. Among those on RA medications, more potent
therapy was associated with a higher prevalence of pain
over multiple sites of the body. Conversely, participants
on more potent medication were less likely to have car-
diovascular disease than those on just steroids. Care
needs to be taken in interpreting these ﬁndings as
genuine negative correlations between disease severity,
treatment and comorbidity. First, the number of partici-
pants who reported RA but were on steroid medication
only was very low (n=12). Second, they may be taking
steroids for other indications. Therefore, conﬁrmation
of their RA diagnosis via biomarkers and linkage to
clinical records is warranted. Third, they may have
severe RA but been unable to take more potent
therapy due to contraindications, including comorbid
conditions. Finally, the association with therapy may
reﬂect reverse causation because patients only continue
on these potent but expensive (biologics) and poten-
tially toxic therapies (DMARDs and biologics) if they
are responding well to them. Some therapies may also
be contraindicated in people with signiﬁcant existing
cardiovascular and other comorbidities. It is also pos-
sible that patients with severe RA may decline more
potent treatment or may be in a period of remission.
The low prevalence of biologic drug treatment in
patients with self-reported RA is noteworthy and sug-
gests that the RA population in UK Biobank may be
much milder than RA in the UK as a whole; patients
with more severe RA appear, as anticipated given the
method of population-based recruitment, under-
represented in the UK Biobank cohort compared with
RA patients in secondary care settings. Patients with less
severe disease are more likely to participate in a study
like UK Biobank. In terms of identifying the ‘cleanest’
RA phenotype, future studies may consider their
primary analysis as treated RA on DMARDs, in the
absence of other systematic rheumatic diseases (such as
systemic lupus erythematosus (SLE) and osteoarthritis),
although there are likely to be patients who do have
RA and osteoarthritis, particularly with increasing age.
There also exists the possibility of using future bio-
marker data (especially citrullinated peptide antibody)
to better characterise the RA phenotype, as used in
other cohorts such as the Women’s Health Initiative.30
UK Biobank is a very large cohort study that is repre-
sentative of the general UK population in terms of
breakdown by age, sex, ethnicity and socioeconomic
status, within the age range recruited. However, in
common with similar observational studies, participants
are not necessarily representative of the general popula-
tion in terms of other characteristics, such as lifestyle.
Therefore, while UK Biobank is of value in identifying
risk factors for the development and progression of
disease, care is required in generalising other measures
such as disease prevalence. Nonetheless, the prevalence
of RA in UK Biobank is broadly in agreement with
similar studies, taking into account that case deﬁnition is
currently based solely on self-report,31 and many other
characteristics—higher cardiovascular disease preva-
lence, socioeconomic gradient, more diabetes, pain and
lower grip strengths—also match up and extend prior
observations. UK Biobank is currently conducting bio-
marker assays, imaging studies and linkage to clinical
records, all of which will improve the case deﬁnition
and stratiﬁcation of RA, and therefore the utility of this
resource for studying RA. The data reported in this
manuscript provide a comprehensive cross-sectional
baseline description of RA and relevant comorbidities in
UK Biobank. Our results provide an initial analysis from
a dataset that is likely to have signiﬁcant future impactful
ﬁndings. We did not exhaustively investigate all possible
comorbidities at this stage, but instead focused on rela-
tively common psychiatric/cardiometabolic diseases and
sociodemographic/anthropometric traits. The follow-up
information being collected via linkage to routine
administrative data sources, including primary care con-
sultations, hospital admissions, prescriptions and deaths,
will provide useful information on the natural history of
RA. Finally, ongoing genotyping will enable researchers
to explore genetic predisposition, gene–environment
interactions and the extent to which the underlying
mechanisms are common to other diseases. As these
further data become available, UK Biobank will become
an increasingly powerful resource to study RA and
related comorbidities. We believe this present paper will
serve as an excellent starting point for future researchers
to interrogate many aspects of RA as UK Biobank data
mature.
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